Market open
Aquestive Therapeutics/$AQST
Aquestive Therapeutics shares are trading higher after the company reported its Q1 results.
28 seconds ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aquestive Therapeutics
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Ticker
$AQST
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
142
ISIN
US03843E1047
Website
AQST Metrics
BasicAdvanced
$221M
-
-$0.59
2.02
-
Price and volume
Market cap
$221M
Beta
2.02
52-week high
$5.48
52-week low
$2.12
Average daily volume
1.5M
Financial strength
Current ratio
4.873
Quick ratio
4.323
Long term debt to equity
-63.299
Total debt to equity
-64.229
Interest coverage (TTM)
-2.44%
Management effectiveness
Return on assets (TTM)
-22.21%
Return on equity (TTM)
111.57%
Valuation
Price to revenue (TTM)
3.774
Price to book
-3.62
Price to tangible book (TTM)
-3.62
Price to free cash flow (TTM)
-4.174
Growth
Revenue change (TTM)
5.29%
Earnings per share change (TTM)
34.24%
3-year revenue growth (CAGR)
1.42%
3-year earnings per share growth (CAGR)
-30.42%
What the Analysts think about AQST
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aquestive Therapeutics stock.
AQST Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AQST Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AQST News
AllArticlesVideos
Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 days ago
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·3 days ago
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aquestive Therapeutics stock?
Aquestive Therapeutics (AQST) has a market cap of $221M as of May 15, 2025.
What is the P/E ratio for Aquestive Therapeutics stock?
The price to earnings (P/E) ratio for Aquestive Therapeutics (AQST) stock is 0 as of May 15, 2025.
Does Aquestive Therapeutics stock pay dividends?
No, Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Aquestive Therapeutics dividend payment date?
Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders.
What is the beta indicator for Aquestive Therapeutics?
Aquestive Therapeutics (AQST) has a beta rating of 2.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.